Updated: Jul 2025
85%
Employees say this is a great place to work
Alnylam is leading the translation of RNA interference into an entire class of innovative medicines with the potential to improve the lives of people with rare genetic, cardiometabolic, hepatic, infectious, central nervous system and ocular diseases. RNAi therapeutics are based on Nobel Prize-winning science and represent a powerful, clinically validated approach to treating a variety of serious, debilitating diseases. Founded in 2002, Alnylam pursues a bold vision of turning scientific opportunity into reality with a robust RNAi therapeutics platform. Alnylam is headquartered in Cambridge, Massachusetts.
Zug
Certification November 2024
Certification November 2023
Certification January 2023
Certification January 2021
Certification February 2020
Certification March 2019
No Data Found
No Data Found
No Data Found
Our employees set us apart. To provide patients with much-needed new medicines, we need a highly motivated, flexible and diverse workforce. We want to continue to attract and retain the best talent and provide them with an inclusive, positive and dynamic working environment where they have a voice and where everything they do adds value to the patients who use our treatments. We want our employees to bring their individual specialties to the table, because progressive and innovative thinking strengthens our company and enables us to continue to offer patients breakthrough medicines.
We have strong values that guide our recruitment decisions, our recognition and appreciation and form the basis of our corporate culture:
- Passion for top performance
- Innovation and research
- Commitment to people
- Open corporate culture
- A sense of urgency
English 
Deutsch 
Français 
